Technical Analysis for IPCI - Intellipharmaceutics International Inc.

Grade Last Price % Change Price Change
grade F 2.98 7.97% 0.22
IPCI closed up 7.97 percent on Friday, September 21, 2018, on 2.32 times normal volume.

Earnings due: Oct 9

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical IPCI trend table...

Date Alert Name Type % Chg
Sep 21 Crossed Above 20 DMA Bullish 0.00%
Sep 21 Calm After Storm Range Contraction 0.00%
Sep 21 Inside Day Range Contraction 0.00%
Sep 21 Wide Bands Range Expansion 0.00%
Sep 21 Up 3 Days in a Row Strength 0.00%
Sep 20 20 DMA Resistance Bearish 7.97%
Sep 20 Volume Surge Other 7.97%
Sep 20 Calm After Storm Range Contraction 7.97%
Sep 20 Wide Bands Range Expansion 7.97%
Sep 20 Oversold Stochastic Weakness 7.97%

Older signals for IPCI ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Intellipharmaceutics International Inc. engages in the research, development, and manufacture of novel and generic controlled and targeted release oral solid dosage drugs in Canada. It has a pipeline of products based on its patented Hypermatrix technology in various stages of development in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, and pain. The company's products under FDA review include Focalin XR, an extended release capsule for hyperactivity disorder; Effexor XR, an extended release capsule for depression; Protonix, a tablet for gastroesophageal reflux disease; Glucophage XR, a tablet for managing type 2 diabetes; Seroquel XR, a tablet for the treatment of schizophrenia, bipolar disorder, and depressive disorder; Lamictal XR, a tablet for anti-convulsant for epilepsy; and Keppra XR, a tablet for the treatment of partial onset seizures for epilepsy, as well as product filed with the FDA comprise Pristiq, a tablet for depression. The company has a license and commercialization agreement with Par Pharmaceutical, Inc. for the development and commercialization of generic Focalin XR. Its late stage development product includes Coreg CR, a capsule for heart failure and hypertension; and phase I clinical trial products include Lyrica, a capsule for Neuropathic pain and Oxycodone Hydrochloride, a controlled release capsule for pain. The company's non-generic products under development include Rexista, an oral formulation for pain relief, and Pregabalin, an extended release capsule for neuropathic pain. The company was founded in 1998 and is based in Toronto, Canada.
Is IPCI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 12.5
52 Week Low 2.3
Average Volume 27,921
200-Day Moving Average 5.2937
50-Day Moving Average 3.1496
20-Day Moving Average 2.914
10-Day Moving Average 3.028
Average True Range 0.4517
ADX 35.0
+DI 12.5302
-DI 25.3186
Chandelier Exit (Long, 3 ATRs ) 2.8449
Chandelier Exit (Short, 3 ATRs ) 3.6551
Upper Bollinger Band 3.7522
Lower Bollinger Band 2.0758
Percent B (%b) 0.54
BandWidth 57.52917
MACD Line -0.0599
MACD Signal Line -0.0533
MACD Histogram -0.0065
Fundamentals Value
Market Cap 92.61 Million
Num Shares 31.1 Million
EPS -0.34
Price-to-Earnings (P/E) Ratio -8.76
Price-to-Sales 5.78
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.34
Resistance 3 (R3) 3.31 3.15 3.28
Resistance 2 (R2) 3.15 3.06 3.17 3.26
Resistance 1 (R1) 3.07 3.01 3.11 3.10 3.24
Pivot Point 2.91 2.91 2.94 2.93 2.91
Support 1 (S1) 2.83 2.82 2.87 2.86 2.72
Support 2 (S2) 2.67 2.77 2.69 2.70
Support 3 (S3) 2.59 2.67 2.68
Support 4 (S4) 2.62